ClinicalTrials.gg
Drug

Surufatinib clinical trials

Also written HMPL-012 and Sulfatinib.

studies test it
82
open now
40
in phase 3
6
first study started
2010

How each study uses surufatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the surufatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Surufatinib
46
SULANDA
4
HMPL-012 and Sulfatinib
2
Surufatinib 250mg/d qd once daily
2
Surufatinib(HMPL-012)
2

Development codes

HMPL-012
18

Other names

Sulfatinib
8

In one entry with another drug

Given together, or one or the other

surufatinib + gemcitabine + nab-paclitaxel
2

Studies by the year they started

82 studies that test it; most in 2021 (17)

Studies that test surufatinib, by start year
YearStudies
20101
20142
20153
20161
20171
20182
20191
20205
202117
202215
202314
202411
20256
20263

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
22
Phase 2
66
Phase 3
6
Phase 4
1
No phase
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 20 · Other 62

Hutchison Medipharma Limited (15) · Sun Yat-sen University (9) · Fudan University (6) · Fujian Cancer Hospital (6) · Tianjin Medical University Cancer Institute and Hospital (4) · Hutchmed (4) · Second Affiliated Hospital, School of Medicine, Zhejiang University (3) · Wuhan Union Hospital, China (3)

Often tested with

Tested in the same studies.

Toripalimab (11) · Sintilimab (9) · Tislelizumab (5) · Gemcitabine (5) · Albumin-Bound Paclitaxel (4) · Paclitaxel (4) · Serplulimab (3) · Pamiparib (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 8

Studies that test surufatinib.

Studies

Open first, then newest update. How each study uses surufatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 82

See all 82 studies that test surufatinib →

Given beside what is tested · 5 — surufatinib is usual care or a partner of the new treatment

What changed recently

From the registry's own updates since Oct 20, 2026.

Codes

What other systems call surufatinib · ClinicalTrials.gg INT001634

  • MeSH (NLM) C000717729surufatinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) B2K5L1L8S9SURUFATINIBConfirmed FDA, NLM, Wikidata
  • Wikidata Q126122215surufatinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C116066SurufatinibOne source FDA
  • DrugBank DB15106One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.